Cargando…

Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine

RATIONALE: There are currently no data supporting specific dosing and weaning strategies for parenteral prostanoid therapy in children with pulmonary arterial hypertension (PAH). OBJECTIVES: To describe the clinical practice of intravenous (IV) or subcutaneous (SC) prostanoid therapy in pediatric PA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Douwes, Johannes M., Zijlstra, Willemijn M. H., Rosenzweig, Erika B., Ploegstra, Mark-Jan, Krishnan, Usha S., Haarman, Meindina G., Roofthooft, Marcus T. R., Postmus, Douwe, Hillege, Hans L., Ivy, D. Dunbar, Berger, Rolf M. F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867364/ https://www.ncbi.nlm.nih.gov/pubmed/34181866 http://dx.doi.org/10.1513/AnnalsATS.202012-1563OC

Ejemplares similares

Cardiac Magnetic Resonance Derived Left Ventricular Eccentricity Index and Right Ventricular Mass Measurements Predict Outcome in Children with Pulmonary Arterial Hypertension
por: Haarman, Meindina G., et al.
Publicado: (2023)

Fate of pulmonary hypertension associated with bronchopulmonary dysplasia beyond 36 weeks postmenstrual age
por: Arjaans, Sanne, et al.
Publicado: (2021)

TBX4 variants and pulmonary diseases: getting out of the ‘Box’
por: Haarman, Meindina G., et al.
Publicado: (2020)

Impact of Parenteral Prostanoids in Pulmonary Arterial Hypertension: The Relevance of Timing
por: Papa, Silvia, et al.
Publicado: (2023)

Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction
por: Hinkamp, Colin A., et al.
Publicado: (2021)

BMPR2 mutations and response to inhaled or parenteral prostanoids: a case series
por: Scelsi, Laura, et al.
Publicado: (2021)

Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag
por: Hinkamp, Colin, et al.
Publicado: (2022)

Factors leading to supranormal cardiac index in pediatric pulmonary hypertension patients treated with parenteral prostanoid therapy
por: Miles, Kimberley G., et al.
Publicado: (2023)

A simulated maximum likelihood procedure for analyzing imprecise trade‐off thresholds between the benefits and harms of medicines
por: Postmus, Douwe, et al.
Publicado: (2022)

Failing Homeostasis of Quadriceps Muscle Energy- and pH Balance During Bicycling in a Young Patient With a Fontan Circulation
por: Haarman, Meindina G., et al.
Publicado: (2019)

Long‐term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension
por: Tamura, Yuichi, et al.
Publicado: (2022)

Muscle strength is reduced in children with pulmonary arterial hypertension
por: Pepplinkhuizen, Shari, et al.
Publicado: (2023)

Prostanoids in bronchoalveolar lavage fluid do not predict outcome in congenital diaphragmatic hernia patients
por: Ijsselstijn, H., et al.
Publicado: (1997)

Adverse drug reactions of montelukast in children and adults
por: Haarman, Meindina G., et al.
Publicado: (2017)

Physiology and pathophysiology of prostanoid receptors
por: Narumiya, Shuh
Publicado: (2007)

Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration
por: Cao, Qi, et al.
Publicado: (2018)

Prostanoid Receptors in the Human Vascular Wall
por: Norel, Xavier
Publicado: (2007)

Prostanoid Metabolites as Biomarkers in Human Disease
por: Idborg, Helena, et al.
Publicado: (2022)

The Link between Prostanoids and Cardiovascular Diseases
por: Beccacece, Livia, et al.
Publicado: (2023)

Pulmonary arterial hypertension associated with pulmonary arteriovenous malformations and pulmonary veno-occlusive disease: A devastating combination
por: Zaaijer, Baukje M., et al.
Publicado: (2021)

Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management
por: Rosenzweig, Erika B., et al.
Publicado: (2019)

Complex Role for E‐Prostanoid 4 Receptors in Hypertension
por: Herrera, Marcela, et al.
Publicado: (2019)

Prostanoid therapies in the management of pulmonary arterial hypertension
por: LeVarge, Barbara L
Publicado: (2015)

Effect of Prostanoids on Human Platelet Function: An Overview
por: Braune, Steffen, et al.
Publicado: (2020)

Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study
por: Roldan Munoz, Sonia, et al.
Publicado: (2021)

What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study
por: Roldan Munoz, Sonia, et al.
Publicado: (2023)

Altered Prostanoid Signaling Contributes to Increased Skin Tumorigenesis in Tpl2 Knockout Mice
por: DeCicco-Skinner, Kathleen L., et al.
Publicado: (2013)

Ventricular–vascular coupling is predictive of adverse clinical outcome in paediatric pulmonary arterial hypertension
por: Dufva, Melanie J, et al.
Publicado: (2021)

Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension
por: Pan, Irene Z., et al.
Publicado: (2020)

Improved homology modeling of the human & rat EP(4) prostanoid receptors
por: Holt, Melissa C., et al.
Publicado: (2019)

When is parenteral nutrition indicated?
por: Berger, Mette M., et al.
Publicado: (2022)

The Immunobiology of Prostanoid Receptor Signaling in Connecting Innate and Adaptive Immunity
por: Harizi, Hedi
Publicado: (2013)

Prostanoids and Resolution of Inflammation – Beyond the Lipid-Mediator Class Switch
por: Schmid, Tobias, et al.
Publicado: (2021)

Prostanoid Signaling in Cancers: Expression and Regulation Patterns of Enzymes and Receptors
por: Ershov, Pavel V., et al.
Publicado: (2022)

The role of thromboxane prostanoid receptor signaling in gastric ulcer healing
por: Yamane, Sakiko, et al.
Publicado: (2021)

Role of prostanoids, nitric oxide and endothelin pathways in pulmonary hypertension due to COPD
por: Alqarni, Abdullah A., et al.
Publicado: (2023)

The Maze of Vasodilator Response Criteria
por: Douwes, J. Menno, et al.
Publicado: (2010)

Laropiprant Attenuates EP3 and TP Prostanoid Receptor-Mediated Thrombus Formation
por: Philipose, Sonia, et al.
Publicado: (2012)

Laropiprant attenuates EP(3) and TP prostanoid receptor-mediated thrombus formation
por: Philipose, Sonia, et al.
Publicado: (2012)

Differential expression of E-type prostanoid receptors 2 and 4 in microglia stimulated with lipopolysaccharide
por: Bonfill-Teixidor, Ester, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_697sagim1drb0vkea7rm0gamme